BioCentury
DATA GRAPHICS | Product Development

Inovio COVID vaccine leans toward T cell responses: Data Byte 

December 29, 2020 2:22 AM UTC

Phase I data for Inovio’s COVID-19 vaccine suggest INO-4800 may stimulate T cell responses more potently than neutralizing responses. The preliminary readout also provided evidence the DNA vaccine induces both CD4+ and CD8+ memory T cell responses.

The company, which announced the data Thursday, ticked up $0.19 to $10.07 Thursday before giving back the gains on Monday, when its shares fell $0.66 to $9.60. ...